%0 Journal Article
%T 2型糖尿病合并肌少症患者骨骼肌质量指数与内脏脂肪面积相关性研究
Correlation between Skeletal Muscle Mass Index and Visceral Fat Area in Type 2 Diabetes Patients with Sarcopenia
%A 王志新
%A 吴乃君
%A 史嘉琳
%A 张妍妍
%J Advances in Clinical Medicine
%P 6850-6854
%@ 2161-8720
%D 2023
%I Hans Publishing
%R 10.12677/ACM.2023.134958
%X 目的：探讨2型糖尿病(Type 2 diabetes, T2DM)合并肌少症患者骨骼肌质量指数与内脏脂肪面积(VFA)的相关性，为T2DM合并肌少症的防治提供参考。方法：选取华北理工大学附属医院2021年10月~2022年7月住院2型糖尿病患者50例，根据生物电阻抗法检测四肢的骨骼肌含量，计算骨骼肌质量指数(ASMI)并根据2014年亚洲肌少症工作组(AWGS)诊断标准将研究对象分为两组：T2DM合并肌少症组20例为病例组，T2DM非肌少症组30例为对照组。收集两组患者年龄、性别、糖尿病病程、身体质量指数(BMI)、糖化血红蛋白(HbA1c)、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL-C)、腰臀比(WHR)、体脂肪及内脏脂肪面积(VFA)。结果：单因素分析中病例组BMI、WHR、体脂肪均低于对照组，差异有统计学意义(P < 0.05)。Logistic回归分析结果显示VFA (P < 0.05，OR值1.111)是影响T2DM合并肌少症患者的影响因素(P < 0.05)。结论：T2DM患者中内脏肥胖与肌少症发生紧密相关，VFA是T2DM合并肌少症的危险因素(P < 0.05)。
Objective: To investigate the correlation between skeletal muscle mass index and visceral fat area (VFA) in Type 2 diabetes mellitus (T2DM) patients with sarcopenia, and to provide reference for the prevention and treatment of T2DM patients with sarcopenia. Methods: Fifty patients with type 2 diabetes who were admitted to the Affiliated Hospital of North China University of Science and Technology from October 2021 to July 2022 were selected. The skeletal muscle content of the limbs was detected by bioresistance method, and the skeletal muscle mass index (ASMI) was calculated. The subjects were divided into two groups according to the diagnostic criteria of Asian sarcopenia Working Group (AWGS) in 2014: 20 patients in T2DM combined with sarcopenia group were the case group and 30 patients in T2DM non-sarcopenia group were the control group. Age, sex, diabe-tes course, body mass index (BMI), glycohemoglobin (HbA1c), triglyceride (TG), total cholesterol (TC), low density lipoprotein (LDL-C), high density lipoprotein (HDL-C), waist-to-hip ratio (WHR), body fat and visceral fat area (VF) were collected in 2 groups A. Results: In univariate analysis, BMI, WHR, body fat and skeletal muscle mass index in case group were lower than those in control group, and the difference was statistically significant (P < 0.05). Logistic regression analysis showed that VFA (P < 0.05, OR 1.111) was the influential factor for T2DM patients with sarcopenia (P < 0.05). Conclusion: Visceral obesity is closely associated with sarcopenia in T2DM patients, and VFA is a risk factor for T2DM patients with sarcopenia (P < 0.05).
%K 2型糖尿病，肌少症，内脏脂肪面积，胰岛素抵抗
Type 2 Diabetes
%K Sarcopenia
%K Visceral Fat Area
%K Insulin Resistance
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=64784